Published January 1, 2018
| Version v1
Journal article
Open
Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas
Creators
- 1. Acibadem Univ, Sch Med, Dept Med Biol, Istanbul, Turkey
- 2. Acibadem Univ, Dept Med Engn, Fac Engn, Istanbul, Turkey
- 3. Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT USA
- 4. Acibadem Univ, Sch Med, Dept Med Stat & Bioinformat, Istanbul, Turkey
- 5. Acibadem Univ, Sch Med, Dept Neurosurg, Inonu Cad Okur Sok 20 Kozyatagi, TR-34742 Istanbul, Turkey
- 6. Acibadem Univ, Sch Med, Dept Med Biochem, Istanbul, Turkey
- 7. Acibadem Univ, Sch Med, Dept Pathol, Istanbul, Turkey
- 8. Acibadem Univ, Fac Arts & Sci, Dept Mol Biol & Genet, Istanbul, Turkey
Description
OBJECTIVE Recent studies have established that hemispheric diffuse gliomas may be grouped into subsets on the basis of molecular markers; these subsets are loosely correlated with the histopathological diagnosis but are strong predictors of clinical tumor behavior. Based on an analysis of molecular and clinical parameters, the authors hypothesized that mutations of the telomerase promoter (TERTp-mut) mark separate oncogenic programs among isocitrate dehydrogenase 1 and/or 2 (IDH) mutant (IDH-mut) and IDH wild-type (IDH-wt) diffuse gliomas independent of histopathology or WHO grade.
Files
bib-541a63c1-5d6a-4f8c-95b6-6eec8c8ebb69.txt
Files
(380 Bytes)
| Name | Size | Download all |
|---|---|---|
|
md5:07ada7f3638a523a5d69d8fc613f1adf
|
380 Bytes | Preview Download |